Avacta Group PLC on Monday revealed it has agreed to collaborate with AI-focused precision medicine business, Tempus AI Inc, to optimise its clinical development process and enable ‘the highest probability of success’.

The oncology-focused life sciences business reported a strategic tie-up in which Chicago-based Tempus AI will grant London-based Avacta access to its ‘multimodal datasets comprising primary tumour samples and associated clinical data’.

Avacta therefore stands to benefit from a substantial data sample pool of over 200,000 patients across varied cancer indications which it can utilise as part of its mission to analyse the biology of the tumour microenvironment and ‘fibroblast activation protein activity’ which its Pre Cision technology is based on.

Avacta Chief Executive Christina Coughlin said: ‘Our pipeline of Pre Cision oncology programs will benefit greatly from an extensive understanding of the tumour microenvironment, FAP biology and both high- and low-FAP expression across solid tumour settings.

‘The Tempus AI real-world database and industry-leading AI capabilities will enable us to better assess the specific patient population most likely to respond to our Pre Cision therapies, enabling faster, smarter clinical development with the highest probability of success.’

This announcement follows on from Thursday’s news that Avacta expanded its oncology pipeline with two novel preclinical assets, AVA6103 and AVA7100, developed to optimise dosing in the tumour environment and improve outcomes for cancer patients.

Shares in Avacta were trading up 0.8% at 61.00 pence on Monday afternoon in London.

Copyright 2024 Alliance News Ltd. All Rights Reserved.